•Leadership watch: Optos, Bascom Palmer, and AOA share updates•How do postop corticosteroids compare to an intracanalicular dexamethasone insert?•Researchers launch free digital tool for pediatric amblyopia care•Pediatric ROP associated with higher strabismus risk•White blood cell counts higher among CRAO patients•Leadership watch: Optos, Bascom Palmer, and AOA share updates•How do postop corticosteroids compare to an intracanalicular dexamethasone insert?•Researchers launch free digital tool for pediatric amblyopia care•Pediatric ROP associated with higher strabismus risk•White blood cell counts higher among CRAO patients
HEADLINES
FEATURED
Lumvoa (veligrotug-vvze) will launch immediately as he second FDA-approved TED treatment—and the first with labeling for both active and chronic TED.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
